Drug Trial Radar · NCT06864169
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Apr 1, 2025
Primary completion
Aug 18, 2026
Study completion Jan 4, 2029
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Mar 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat certain types of advanced gastrointestinal (GI) cancers. The study medicine raludotatug deruxtecan (also called MK-5909, R-DXd, or DS-6000a) is a type of medicine called an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The main goal of this study is to learn if the cancer responds to treatment (gets smaller or goes away).
Conditions
- Gastrointestinal Cancer
Interventions
Raludotatug Deruxtecan (R-DXd)Biological
Administered via intravenous (IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Approximately 15 months
Locations
41 sites in 10 countries. Site status is shown where the registry gives one.
Yale New Haven Hospital ( Site 0375)
New Haven, Connecticut
Sibley Memorial Hospital ( Site 0372)
Washington D.C., District of Columbia
Mt Sinai Comprehensive Cancer Center ( Site 0345)
Miami Beach, Florida
St. Vincent Healthcare Frontier Cancer Center ( Site 0347)
Billings, Montana
Morristown Medical Center ( Site 0349)
Morristown, New Jersey
University Hospitals Cleveland Medical Center ( Site 0369)
Cleveland, Ohio
University of Virginia Cancer Center ( Site 0365)
Charlottesville, Virginia
University of Wisconsin Carbone Cancer Center ( Site 0348)
Madison, Wisconsin
Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0006)
La Rioja, Argentina
Instituto de Investigaciones Clinicas Mar del Plata ( Site 0001)
Mar del Plata, Buenos Aires, Argentina
Nefra Medical Care - CEMIC Saavedra ( Site 0008)
Buenos Aires, Buenos Aires F.D., Argentina
Instituto Medico de la Fundacion Estudios Clinicos ( Site 0007)
Rosario, Santa Fe Province, Argentina
Sunnybrook Research Institute ( Site 0044)
Toronto, Ontario, Canada
Princess Margaret Cancer Centre ( Site 0041)
Toronto, Ontario, Canada
Centre Hospitalier de l'Université de Montréal ( Site 0042)
Montreal, Quebec, Canada
FALP ( Site 0062)
Santiago, Region M. de Santiago, Chile
Centro de Estudios Clínicos SAGA ( Site 0064)
Santiago, Region M. de Santiago, Chile
Clínica UC San Carlos de Apoquindo ( Site 0066)
Santiago, Region M. de Santiago, Chile
Bradfordhill ( Site 0069)
Santiago, Region M. de Santiago, Chile
Pitie Salpetriere University Hospital ( Site 0082)
Paris, France
Centre François Baclesse ( Site 0085)
Caen, Calvados, France
Institut Regional du Cancer Montpellier ( Site 0084)
Montpellier, Herault, France
Gustave Roussy ( Site 0081)
Villejuif, Val-de-Marne, France
Prince of Wales Hospital ( Site 0122)
Hksar, Hong Kong
Queen Mary Hospital ( Site 0121)
Hksar, Hong Kong
Hospital Clinic de Barcelona ( Site 0223)
Barcelona, Spain
Hospital General Universitario Gregorio Marañón ( Site 0225)
Madrid, Spain
Hospital Universitario Fundacion Jimenez Diaz ( Site 0224)
Madrid, Spain
Institut Català d'Oncologia (ICO) - Badalona ( Site 0222)
Badalona, Barcelona, Spain
Hospital Universitario Marqués de Valdecilla ( Site 0221)
Santander, Cantabria, Spain
Universitaetsspital Zuerich ( Site 0242)
Zurich, Switzerland
Universitaetsspital Basel ( Site 0241)
Basel, Canton of Basel-City, Switzerland
Hôpitaux Universitaires de Genève (HUG) ( Site 0245)
Geneva, Canton of Geneva, Switzerland
China Medical University Hospital ( Site 0267)
Taichung, Taiwan
Taichung Veterans General Hospital ( Site 0265)
Taichung, Taiwan
National Cheng Kung University Hospital ( Site 0263)
Tainan, Taiwan
National Taiwan University Hospital ( Site 0261)
Taipei, Taiwan
Mackay Memorial Hospital ( Site 0266)
Taipei, Taiwan
Taipei Veterans General Hospital ( Site 0262)
Taipei, Taiwan
Ramathibodi Hospital. ( Site 0282)
Bangkok, Bangkok, Thailand
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.